Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong · Delayed Price · Currency is HKD 61.00
-2.20 (-3.48%)
Sep 10, 2026, 1:14 PM HKT
Nanjing Leads Biolabs Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 858.66 | 1,221 | 372.54 | 247.52 |
Short-Term Investments | 383.39 | 326.89 | - | - |
Trading Asset Securities | - | - | 166.18 | 100.13 |
Cash & Short-Term Investments | 1,242 | 1,548 | 538.72 | 347.65 |
Cash Growth | 174.97% | 187.36% | 54.96% | - |
Inventory | 70.31 | 58.02 | - | - |
Other Current Assets | 94.59 | 84.17 | 57.59 | 19.47 |
Total Current Assets | 1,439 | 1,690 | 596.31 | 367.12 |
Property, Plant & Equipment | 48.32 | 49.02 | 47.57 | 61.09 |
Other Intangible Assets | 1.99 | 1.76 | - | - |
Other Long-Term Assets | 50.17 | 40.42 | 25.57 | 19.27 |
Total Assets | 1,539 | 1,781 | 669.44 | 447.48 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 6.77 | 6.49 | 3.52 | 0.22 |
Accrued Expenses | 46 | 41.87 | 34.26 | 23.33 |
Current Portion of Long-Term Debt | 355.22 | 260.09 | 255.21 | 61 |
Current Portion of Leases | 7.89 | 7.07 | 5.72 | 4.31 |
Current Income Taxes Payable | 0.95 | 0.98 | 0.78 | 0.9 |
Current Unearned Revenue | 172.68 | 178.21 | 84.22 | - |
Other Current Liabilities | 8.36 | 7.5 | 14.63 | 1,305 |
Total Current Liabilities | 597.87 | 502.2 | 398.34 | 1,395 |
Long-Term Leases | 10.28 | 13.4 | 5.55 | 1.78 |
Total Liabilities | 608.15 | 515.61 | 403.88 | 1,396 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 198.89 | 198.89 | 156.5 | 17.02 |
Retained Earnings | - | -406.98 | -195.56 | -982.76 |
Treasury Stock | -193.62 | -72.67 | - | - |
Comprehensive Income & Other | 925.56 | 1,547 | 304.62 | 16.93 |
Shareholders' Equity | 930.83 | 1,266 | 265.56 | -948.81 |
Total Liabilities & Equity | 1,539 | 1,781 | 669.44 | 447.48 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 373.39 | 280.56 | 266.48 | 67.09 |
Net Cash (Debt) | 868.66 | 1,267 | 272.24 | 280.57 |
Net Cash Growth | 470.92% | 365.57% | -2.97% | - |
Net Cash Per Share | 4.47 | 7.28 | 1.81 | 1.94 |
Filing Date Shares Outstanding | 195.12 | 198.89 | 156.5 | 144.85 |
Total Common Shares Outstanding | 195.12 | 198.89 | 156.5 | 144.85 |
Working Capital | 840.63 | 1,188 | 197.97 | -1,027 |
Book Value Per Share | 4.77 | 6.36 | 1.70 | -6.55 |
Tangible Book Value | 928.84 | 1,264 | 265.56 | -948.81 |
Tangible Book Value Per Share | 4.76 | 6.36 | 1.70 | -6.55 |
Machinery | - | 82.65 | 75.61 | 74.21 |
Construction In Progress | - | 1 | - | 0.36 |
Leasehold Improvements | - | 25.85 | 25.85 | 24.63 |